The EU-European Union drug regulator has released findings that there may be a link between vaccination with the new coronavirus vaccine developed by AstraZeneca and others and blood clots confirmed after vaccination.

British officials have also examined cases of confirmed blood clots and have announced that they will recommend another vaccine for people under the age of 30.

However, all regulators said it was important to continue vaccination, saying that the benefits of the vaccine outweigh the risks.

Regarding the vaccine jointly developed by AstraZeneca and Oxford University, there have been reports of cases in which blood clots were confirmed after inoculation.

The EMA = European Medicines Agency, which has been investigating this, held a press conference on the 7th, saying that blood clots "should be added to the list of side reactions of AstraZeneca's vaccine" and may be related to the vaccine. Showed the recognition.

Most of the cases of blood clots investigated by EMA are women under 60 years old within 2 weeks after vaccination, and it is confirmed in veins of the brain and abdomen, but those showing bias by specific age or gender Not for now.

British regulators and independent committee officials also said in a press conference on the 7th that young people are more likely to have adverse events, albeit slightly, and Astra for those under the age of 30. He said he would recommend using another vaccine, such as Pfizer, instead of the Zeneca vaccine.

According to UK regulators, the risk of having a blood clot is extremely rare in about 4 out of 1 million people, and both UK and EU regulators will continue to say that the benefits of vaccination outweigh the risks. He said it was important to proceed with the inoculation.

WHO "Evaluation compared to risk"

The World Health Organization's International Advisory Board, which is investigating vaccine safety following the results of investigations by EU and UK regulators, issued a statement on the 7th, with current information on vaccination and blood clots. While it is reasonable to think that it may be relevant, he points out that it is not yet finalized and that more detailed research is needed.

"Rare adverse events must be evaluated against the risk of dying from infection with the new coronavirus," he said.

AstraZeneca “Proceed with verification”

AstraZeneca issued a statement on the 7th, stating that it would cooperate with the request to add blood clots to the list as a very rare side reaction.

He says that he is already examining the situation and possible mechanisms of individual cases in which blood clots have been confirmed.

On the other hand, AstraZeneca said, "Each authority has reaffirmed that the vaccine is highly effective against the aggravation of the new coronavirus and the benefits outweigh the risks."

Italy / Spain Limited to 60 years old and over

Italian health officials announced at a press conference on the 7th that vaccinations developed by AstraZeneca and others will be limited to those over 60 years old.

However, the benefits of vaccination outweigh the risks, and those who received the first vaccination with AstraZeneca will continue to receive the second vaccination even if they are under the age of 60.

Spain also announced at a press conference on the night of the 7th that AstraZeneca vaccination would be limited to people between the ages of 60 and 65.

In Europe, France has announced that it will inoculate people aged 55 and over, and Germany will inoculate people aged 60 and over from March.